<DOC>
	<DOC>NCT01138735</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of EpiduoÂ® (adapalene and benzoyl peroxide) Gel 0.1%/2.5% administered once daily for up to 12 weeks in subjects 9 to 11 years of age with acne vulgaris.</brief_summary>
	<brief_title>Epiduo Pediatric Acne Study</brief_title>
	<detailed_description />
	<mesh_term>Adapalene, Benzoyl Peroxide Drug Combination</mesh_term>
	<mesh_term>Adapalene</mesh_term>
	<mesh_term>Benzoyl Peroxide</mesh_term>
	<criteria>Clinical diagnosis of acne vulgaris with facial involvement Score of 3 (moderate) on the Investigator's Global Assessment (IGA) scale A minimum of 20 but not more than 100 total lesions (Noninflammatory and/or Inflammatory) on the face (including the nose) at Baseline Acne nodule or acne cyst Acne conglobata, acne fulminans, secondary acne (chloracne, druginduced acne, etc.), or severe acne requiring systemic treatment Underlying diseases and/or dermatologic conditions that require the use of interfering topical or systemic therapy or that might interfere with study assessments Use of prohibited medications prior to the study and/or are unwilling to refrain from such use during the study</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>